Posts tagged: patient

We report a 25-year-old woman who developed optic neuritis and encephalomyelitis following primary Sjogren’s syndrome (SjS).

Purpose. To report changes in retinal nerve fiber layer (RNFL) thickness in a patient with neuromyelitis optica (NMO).

We report the case of a 60-year-old woman with myasthenia gravis (MG) and Basedow’s disease who seven years after thymectomy developed subacute myelitis, a limited form of neuromyelitis optica (NMO). The patient presented with a centrally located long spinal cord lesion (LCL) on cervical cord MRI, anti-aquaporin 4 (AQP4) antibody in serum, and HLA DPB1*0501

We report the case of a 31-year-old woman who presented with neuromyelitis optica (NMO) associated with Sjogren syndrome and distal renal tubular acidosis. She was hospitalized because of cervical transverse myelopathy and right optic neuritis. She had been clinically diagnosed with Sjogren syndrome, with a high titer of anti-SS-A antibody (1:500) and anti-SS-B antibody (1:498)

OBJECTIVE: To construct the human aquaporin-4 (AQP4) expressing vector and detect anti-AQP4 antibody in serum of patients with neuromyelitis optica (NMO). METHODS: RNA was extracted from human glioblastoma and AQP4 cDNA obtained through RT-PCR.The fragment was cloned into the lentiviral expressing vector (iDUET101) and transformed into competent strain Hb101 for later amplification; plasmids were extracted from the amplified positive-bacteria-colony, sequenced and transfected into HEK-293T cells

In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy.

Neuromyelitis optica (NMO)-immunoglobulin G (IgG) is a clinically validated serum biomarker that distinguishes relapsing central nervous system (CNS) infl ammatory demyelinating disorders related to NMO from multiple sclerosis.

Autologous peripheral hematopoietic stem cell transplantation (APHSCT) was performed to treat a patient with neuromyelitis optica. We observed that the patient achieved clinical remission after APHSCT during 12 months of follow-up

OBJECTIVE: Neuromyelitis optica (NMO) is currently considered a severe relapsing CNS demyelinating disorder that is associated with aquaporin-4 immunoglobulin G (NMO-IgG) while in earlier reports of NMO in childhood it has been described as a benign and monophasic disorder. This study was performed to analyze the prevalence and the clinical course of NMO in a European pediatric cohort of patients with demyelinating CNS disorders

Neuromyelitis optica (NMO) is an aggressive demyelinating disease that typically affects the optic nerves and spinal cord. While it is increasingly recognized that cerebral lesions are common in NMO, there have been no reported cases of NMO presenting with psychiatric symptoms and polydipsia.

Background: Neuromyelitis Optica (NMO) and its spectrum disorders (NMOSD), which include recurrent transverse myelitis (rTM) and recurrent optic neuritis (rON) are demyelinating diseases of the central nervous system (CNS).

The detection of aquaporin-4 (AQP4) antibodies in neuromyelitis optica (NMO) led to a breakthrough in diagnosing NMO. To date, different assays to detect these antibodies are available.

The Power of Rare.

Power of Rare Book Cover

Victoria Jackson’s new book, THE POWER OF RARE: A Blueprint for a Medical Revolution, shares how a revolutionary model was created to speed discoveries that help empower patients and save lives.

No Thanks